Insulin glargine_Lixisenatide(1)

Treatment with glucagon-like peptide receptor agonists reduces the risk for major adverse cardiovascular events among people with type 2 diabetes, indicate findings from a large meta-analysis.

Macroalbuminuric patients with type 2 diabetes and a recent acute coronary event who are treated with lixisenatide may experience a reduction in their urinary albumin-to-creatinine ratio, suggests an exploratory post-hoc analysis of the ELIXA trial.

A meta-analysis published in The Lancet Diabetes & Endocrinology is suggestive of a class cardioprotective effect for the glucagon-like peptide-1 receptor agonists.

Results of a post-hoc analysis suggest that the efficacy of lixisenatide is not compromised among patients with type 2 diabetes who have mild or moderate renal impairment.

Results of the placebo-controlled GetGoal-O trial suggest that adding lixisenatide to existing diabetes treatment improves glycemic control among nonfrail older patients with uncontrolled type 2 diabetes.

Use of a titratable, fixed-ratio combination of insulin glargine and the glucagon-like peptide 1 receptor agonist lixisenatide helps overweight patients with long-standing Type 2 diabetes to attain glycaemic control, shows a randomised trial.